Europe Cardiac Safety Services Market, By Services (ECG/Holter Measurements, Blood Pressure Measurements, In Vitro Cardiac Safety Assessment Services, Cardiovascular Imaging, Real-Time Telemetry Monitoring, Central Over-Read of ECGS, Non-Invasive Cardiac Imaging, Physiologic Stress Testing, Thorough QT Studies, TQT and Exposure Response Modeling, Platelet Aggregation and Other Services), Phase (Phase 1, Phase 2 and Phase 3), Type (Integrated Services and Standalone Services), End User (Pharmaceuticals & Biopharmaceuticals Companies, Contract Research Organizations and Academic and Research Institute) Industry Trends and Forecast to 2029.
Market Analysis and Insights
Europe cardiac safety services market is driven by the factors such as an increase in the number of clinical trials, a growing number of the major market players and the innovation in technology, which enhance its demand, as well as increasing investment in research and development, leads to the market growth. Currently, various research studies are taking place, which is expected to create a competitive advantage for manufacturers to develop new and innovative cardiac safety services systems, which is expected to provide various other opportunities in the cardiac safety services market. However, the strict government regulations on approval are expected to hamper the growth.
Europe cardiac safety services market report provides details of market share, new developments, and product pipeline analysis, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an analyst brief, our team will help you create a revenue impact solution to achieve your desired goal. The scalability and business expansion of the retail units in the developing countries of various regions and partnership with suppliers for safe distribution of machine and drugs products are the major drivers that propelled the market's demand in the forecast period.
Europe cardiac safety services market is supportive and aims to reduce the progression of the disease. Data Bridge Market Research analyses that Europe cardiac safety services Market will grow at a CAGR of 14.8% during the forecast period of 2022 to 2029.
|
Report Metric |
Details |
|
Forecast Period |
2022 to 2029 |
|
Base Year |
2021 |
|
Historic Years |
2020 (Customizable to 2019 - 2014) |
|
Quantitative Units |
Revenue in USD Million, Pricing in USD |
|
Segments Covered |
By Services (ECG/Holter Measurements, Blood Pressure Measurements, In Vitro Cardiac Safety Assessment Services, Cardiovascular Imaging, Real-Time Telemetry Monitoring, Central Over-Read of ECGS, Non-Invasive Cardiac Imaging, Physiologic Stress Testing, Thorough QT Studies, TQT and Exposure Response Modeling, Platelet Aggregation and Other Services), Phase (Phase 1, Phase 2 and Phase 3), Type (Integrated Services and Standalone Services), End User (Pharmaceuticals & Biopharmaceuticals Companies, Contract Research Organizations and Academic and Research Institute) |
|
Countries Covered |
Germany, France, U.K., Italy, Spain, Turkey, Russia, Netherlands, Switzerland, Belgium and Rest of Europe |
|
Market Players Covered |
Koninklijke Philips N.V., Laboratory Corporation of America Holdings, IQVIA, Medpace, Ncardia, Certara, Eurofins Scientific, SGS SA, Banook, and Celerion among others |
Market Definition:
Cardiac safety services generally help support and design clinical trials and other research needed to monitor heart safety. The demand for cardiac safety services market has been increased in both developed well as in developing countries and the reason behind this is the increasing number of clinical trials and product launch. The cardiac safety services market is growing due to introduction of innovative products, increasing in technological products and rising disposable income. The market will grow in forecasted period due to exploration of emerging markets, strategic initiatives by market players, increasing healthcare expenditure.
Europe Cardiac Safety Services Market Dynamics
Drivers
- Increase in the number of clinical trials
A clinical trial is a well-structured system that is way back hundreds of years and is still the backbone of the regulatory requirements required for a drug to be approved. Recently there has been much advancement in the clinical trial field, which has increased the number of clinical trials and is expected to propel the market growth.
There have been various changes in the regulatory of the clinical trials, which has increased the number of clinical trials and their positive results-
For instance,
- According to the article by Medical News, there has been a significant increase in the number of trials due to the rise in the quality of clinical trials, such as mandatory training of all staff. Also, in 2017, NIH stated that all investigators and staff should be trained on good clinical practice (GCP) in trials that NIH funds
Increase in healthcare expenditure and funding
The expanse of money used by a country on its healthcare and its growth rate over time is inclined by a wide variety of economic and social factors, including the financing arrangements and structure of the organization of the health system.
Healthcare expenditure has increased across developed countries and emerging economies as the disposable income of people are growing. The more money is spent on healthcare; the healthier a country's population is.
Opportunity
- Increase in new drug development
The clinical trials are vital for discovering and developing new drugs for disease treatment. It is the best way researchers can find out what treatments work or don't work on humans. The drug development is characterized as forming new treatment as medicines or devices for curing various diseases such as cancer, endocrine, metabolic, and others.
- Thus, clinical trials are the most effective way to ensure the safety and efficacy of the therapeutic drug before launching in the market and human consumption that includes cardiac safety evaluation which is an essential part before any medical product goes into the market
Restraint/Challenge
The proper assessment and reporting of clinical cardiac safety data is essential. Approval and product recall for any medical products depend on cardiac safety evaluation. So it is necessary to provide and conduct cardiac safety evaluation according to the legal procedure, otherwise it leads to late approval of the product which is expected to restrain the market growth.
For instance,
- According to the article by IQVIA, there were 47 instances of post-marketing withdrawal of drugs between 1957 and 2007, in which 45% of these were due to concerns regarding cardiovascular toxicity. Similarly, 27% of the potential new drug molecules that failed in the preclinical phase in the last two decades did so because of cardiovascular toxicity as they did not meet the required regulatory
Europe Cardiac Safety Services Market Segmentation
Europe cardiac safety services market is categorized into type, services, phase and end user. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
Services
- ECG/holter measurements
- Blood pressure measurements
- In vitro cardiac safety assessment services
- Cardiovascular imaging
- Real-time telemetry monitoring
- Central over-read of ECGS
- Non-invasive cardiac imaging
- Physiologic stress testing
- Thorough QT studies
- TQT and exposure response modeling
- Platelet aggregation
- Other services
On the basis of services, the cardiac safety services market is segmented into ECG/Holter measurements, blood pressure measurements, in vitro cardiac safety assessment services, cardiovascular imaging, real-time telemetry monitoring, central over-read of ECGS, non-invasive cardiac imaging, physiologic stress testing, thorough QT studies, TQT and exposure response modeling, platelet aggregation and other services
Phase
- Phase 1
- Phase 2
- Phase 3
On the basis of phases, the cardiac safety services market is segmented into phase 1, phase 2, and phase 3.
Type
- Integrated services
- Standalone services
On the basis of type, the cardiac safety services market is segmented into integrated services and standalone services.
End User
- Pharmaceuticals & Biopharmaceuticals Companies
- Contract Research Organizations
- Academic and Research Institute
On the basis of end user, the cardiac safety services market is segmented pharmaceuticals & biopharmaceuticals companies, contract research organizations, and academic and research institute.
Cardiac Safety Services Regional Analysis/Insights
The cardiac safety services is analysed and market size insights and trends are provided by type, services, phase and end user as referenced above.
The countries covered in the cardiac safety services report are Germany, France, U.K., Italy, Spain, Turkey, Russia, Netherlands, Switzerland, Belgium and Rest of Europe.
Germany is expected to dominate due to increase in new drug development and healthcare expenditure.
The country section of the report also provides individual market impacting factors and changes in market regulation that impact the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Europe brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Cardiac Safety Services Analysis
Europe cardiac safety services market competitive landscape provides details by the competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, Europe presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus on cardiac safety services market.
Some major players in the market are Koninklijke Philips N.V., Laboratory Corporation of America Holdings, IQVIA, Medpace, Ncardia, Certara, Eurofins Scientific, SGS SA, Banook, and Celerion among others.
Research Methodology
Data collection and base year analysis are done using data collection modules with large sample sizes. The market data is analysed and estimated using market statistical and coherent models. In addition, market share analysis and key trend analysis are the major success factors in the market report. The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Europe Vs Regional and Vendor Share Analysis. Please request analyst call in case of further inquiry.
SKU-
احصل على إمكانية الوصول عبر الإنترنت إلى التقرير الخاص بأول سحابة استخبارات سوقية في العالم
- لوحة معلومات تحليل البيانات التفاعلية
- لوحة معلومات تحليل الشركة للفرص ذات إمكانات النمو العالية
- إمكانية وصول محلل الأبحاث للتخصيص والاستعلامات
- تحليل المنافسين باستخدام لوحة معلومات تفاعلية
- آخر الأخبار والتحديثات وتحليل الاتجاهات
- استغل قوة تحليل المعايير لتتبع المنافسين بشكل شامل
Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF EUROPE CARDIAC SAFETY SERVICES MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 SERVICES LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET END USER GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PORTERS FIVE FORCES
4.2 PESTEL ANALYSIS
5 EPIDEMIOLOGY
5.1 INCIDENCE OF ALL BY GENDER
5.2 TREATMENT RATE
5.3 MORTALITY RATE
5.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL
6 INDUSTRY INSIGHT
6.1 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES
6.2 PATENT ANALYSIS
6.3 PATENT FLOW DIAGRAM
6.4 KEY PATIENT ENROLLMENT STRATEGIES
6.5 PRICING STRATEGY
7 EUROPE CARDIAC SAFETY SERVICES MARKET: REGULATIONS
8 MARKET OVERVIEW
8.1 DRIVERS
8.1.1 INCREASE IN THE NUMBER OF CLINICAL TRIALS
8.1.2 INCREASE IN HEALTHCARE EXPENDITURE AND FUNDING
8.1.3 INCREASE IN STRATEGIC INITIATIVES BY MAJOR MARKET PLAYERS
8.1.4 INCREASE IN R&D ACTIVITIES
8.2 RESTRAINTS
8.2.1 HIGH COST OF CARDIAC SAFETY EVALUATION
8.2.2 STRICT REGULATORY
8.3 OPPORTUNITIES:
8.3.1 INCREASE IN NEW DRUG DEVELOPMENT
8.3.2 RISE IN THE EXPANSION OF THE CARDIAC SAFETY SERVICES
8.4 CHALLENGES
8.4.1 TIME-CONSUMING PROCEDURE
8.4.2 LACK OF SKILLED PERSON TO OPERATE DEVICES DURING CARDIAC SAFETY EVALUATION
9 EUROPE CARDIAC SAFETY SERVICES MARKET, BY SERVICES
9.1 OVERVIEW
9.2 ECG/HOLTER MEASUREMENTS
9.3 BLOOD PRESSURE MEASUREMENTS
9.4 IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES
9.4.1 HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS
9.4.1.1 1 CONCENTRATIONS
9.4.1.2 4 CONCENTRATIONS
9.4.2 COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA)
9.4.2.1 3 CONCENTRATIONS
9.4.2.2 5 CONCENTRATIONS
9.4.3 IN VITRO HERG ASSAY
9.4.4 OTHERS
9.5 CARDIOVASCULAR IMAGING
9.6 REAL TIME TELEMETRY MONITORING
9.7 CENTRAL OVER-READ OF ECGS
9.8 NON-INVASIVE CARDIAC IMAGING
9.9 PHYSIOLOGIC STRESS TESTING
9.1 THOROUGH QT STUDIES
9.11 TQT AND EXPOSURE RESPONSE MODELLING
9.12 PLATELET AGGREGATION
9.13 OTHERS
10 EUROPE CARDIAC SAFETY SERVICES MARKET, BY PHASE
10.1 OVERVIEW
10.2 PHASE I
10.3 PHASE II
10.4 PHASE III
11 EUROPE CARDIAC SAFETY SERVICES MARKET, BY TYPE
11.1 OVERVIEW
11.2 INTEGRATED SERVICES
11.3 STANDALONE SERVICES
12 EUROPE CARDIAC SAFETY SERVICES MARKET, BY END USER
12.1 OVERVIEW
12.2 PHARMACEUTICALS & BIOPHARMACEUTICALS COMPANIES
12.3 CONTRACT RESEARCH ORGANIZATIONS
12.4 ACADEMIC AND RESEARCH INSTITUTE
13 EUROPE CARDIAC SAFETY SERVICES MARKET, BY REGION
13.1 EUROPE
13.1.1 GERMANY
13.1.2 FRANCE
13.1.3 U.K.
13.1.4 ITALY
13.1.5 SPAIN
13.1.6 TURKEY
13.1.7 RUSSIA
13.1.8 NETHERLANDS
13.1.9 SWITZERLAND
13.1.10 BELGIUM
13.1.11 REST OF EUROPE
14 EUROPE CARDIAC SAFETY SERVICES MARKET: COMPANY LANDSCAPE
14.1 COMPANY SHARE ANALYSIS: EUROPE
15 COMPANY PROFILE
15.1 EUROFINS SCIENTIFIC
15.1.1 COMPANY SNAPSHOT
15.1.2 REVENUE ANALYSIS
15.1.3 COMPANY SHARE ANALYSIS
15.1.4 PRODUCT PORTFOLIO
15.1.5 RECENT DEVELOPMENTS
15.1.5.1 AGREEMENTS
15.1.5.2 ACQUISITION
15.2 PPD INC. (SUBSIDIARY OF THERMO FISHER SCIENTIFIC INC)
15.2.1 COMPANY SNAPSHOT
15.2.2 REVENUE ANALYSIS
15.2.3 COMPANY SHARE ANALYSIS
15.2.4 PRODUCT PORTFOLIO
15.2.5 RECENT DEVELOPMENT
15.2.5.1 INVESTMENT
15.3 KONINKLIJKE PHILIPS N.V.
15.3.1 COMPANY SNAPSHOT
15.3.2 REVENUE ANALYSIS
15.3.3 COMPANY SHARE ANALYSIS
15.3.4 PRODUCT PORTFOLIO
15.3.5 RECENT DEVELOPMENT
15.3.5.1 ACQUISITION
15.4 IQVIA
15.4.1 COMPANY SNAPSHOT
15.4.2 REVENUE ANALYSIS
15.4.3 COMPANY SHARE ANALYSIS
15.4.4 PRODUCT PORTFOLIO
15.4.5 RECENT DEVELOPMENTS
15.4.5.1 ACQUISITION
15.5 LABORATORY CORPORATION OF AMERICA HOLDINGS
15.5.1 COMPANY SNAPSHOT
15.5.2 REVENUE ANALYSIS
15.5.3 COMPANY SHARE ANALYSIS
15.5.4 PRODUCT PORTFOLIO
15.5.5 RECENT DEVELOPMENTS
15.5.5.1 NEW LABORATORY
15.5.5.2 ACQUISITION
15.6 BANOOK
15.6.1 COMPANY SNAPSHOT
15.6.2 PRODUCT PORTFOLIO
15.6.3 RECENT DEVELOPMENT
15.6.3.1 AGREEMENT
15.7 BIOTRIAL
15.7.1 COMPANY SNAPSHOT
15.7.2 PRODUCT PORTFOLIO
15.7.3 RECENT DEVELOPMENT
15.7.3.1 NEW CENTER OPENING
15.8 CELERION
15.8.1 COMPANY SNAPSHOT
15.8.2 PRODUCT PORTFOLIO
15.8.3 RECENT DEVELOPMENT
15.8.3.1 NEW CENTER OPENING
15.9 CERTARA
15.9.1 COMPANY SNAPSHOT
15.9.2 REVENUE ANALYSIS
15.9.3 PRODUCT PORTFOLIO
15.9.4 RECENT DEVELOPMENTS
15.9.4.1 CONTRACT
15.9.4.2 ACQUISITION
15.1 CLARIO
15.10.1 COMPANY SNAPSHOT
15.10.2 PRODUCT PORTFOLIO
15.10.3 RECENT DEVELOPMENT
15.10.3.1 PRODUCT EXPANSION
15.11 MEDPACE
15.11.1 COMPANY SNAPSHOT
15.11.2 REVENUE ANALYSIS
15.11.3 PRODUCT PORTFOLIO
15.11.4 RECENT DEVELOPMENTS
15.11.4.1 ACQUISITION
15.12 NCARDIA
15.12.1 COMPANY SNAPSHOT
15.12.2 PRODUCT PORTFOLIO
15.12.3 RECENT DEVELOPMENT
15.12.3.1 PARTNERSHIP
15.13 NEXEL CO., LTD
15.13.1 COMPANY SNAPSHOT
15.13.2 PRODUCT PORTFOLIO
15.13.3 RECENT DEVELOPMENTS
15.13.3.1 JOINT VENTURE
15.13.3.2 PARTNERSHIP
15.14 PHYSIOSTIM
15.14.1 COMPANY SNAPSHOT
15.14.2 PRODUCT PORTFOLIO
15.14.3 RECENT DEVELOPMENT
15.14.3.1 PARTNERSHIP
15.15 RICHMOND PHARMACOLOGY
15.15.1 COMPANY SNAPSHOT
15.15.2 PRODUCT PORTFOLIO
15.15.3 RECENT DEVELOPMENT
15.15.3.1 EVENT
15.16 SGS SA
15.16.1 COMPANY SNAPSHOT
15.16.2 REVENUE ANALYSIS
15.16.3 PRODUCT PORTFOLIO
15.16.4 RECENT DEVELOPMENT
15.16.4.1 ACQUISITION
15.17 SHANGHAI MEDICILON INC.
15.17.1 COMPANY SNAPSHOT
15.17.2 PRODUCT PORTFOLIO
15.17.3 RECENT DEVELOPMENTS
15.17.3.1 PARTNERSHIP
15.17.3.2 PARTNERSHIP
16 QUESTIONNAIRE
17 RELATED REPORTS
List of Table
TABLE 1 PROPORTION OF WOMEN IN CLINICAL STUDIES, ACCORDING TO DEVELOPMENT PHASE
TABLE 2 PROBABILITY OF SUCCESS BY CLINICAL TRIAL PHASE TO THERAPEUTIC AREA
TABLE 3 MORTALITY RATES FROM CLINICAL TRIALS AND EUROPEAN SAFETY AND EXPOSURE SURVEY (ESES), DEATHS PER 100 (PYE)
TABLE 4 ADHERENCE RATE TO COMMON CARDIOVASCULAR MEDICATION
TABLE 5 PROPORTION OF WOMEN IN CLINICAL STUDIES, ACCORDING TO DEVELOPMENT PHASE
TABLE 6 INITIATIVES TO INCREASE ENROLLMENT IN CLINICAL TRIALS AMONG UNDERREPRESENTED POPULATIONS
TABLE 7 ESTIMATED COST OF CARDIAC SAFETY EVALUATION DEVICES
TABLE 8 EUROPE CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 9 EUROPE ECG/HOLTER MEASUREMENTS IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 10 EUROPE BLOOD PRESSURE MEASUREMENTS IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 11 EUROPE IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 12 EUROPE IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 13 EUROPE HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 14 EUROPE COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 15 EUROPE CARDIOVASCULAR IMAGING IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 16 EUROPE REAL TIME TELEMETRY MONITORING IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 17 EUROPE CENTRAL OVER-READ OF ECGS IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 18 EUROPE NON-INVASIVE CARDIAC IMAGING IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 19 EUROPE PHYSIOLOGIC STRESS TESTING IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 20 EUROPE THOROUGH QT STUDIES IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 21 EUROPE TQT AND EXPOSURE RESPONSE MODELLING IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 22 EUROPE PLATELET AGGREGATION IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 23 EUROPE OTHERS IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 24 EUROPE CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)
TABLE 25 EUROPE PHASE I IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 26 EUROPE PHASE II IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 27 EUROPE PHASE III IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 28 EUROPE CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 29 EUROPE INTEGRATED SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 30 EUROPE STANDALONE SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 31 EUROPE CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 32 EUROPE PHARMACEUTICALS & BIOPHARMACEUTICALS COMPANIES IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 33 EUROPE CONTRACT RESEARCH ORGANIZATIONS IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 34 EUROPE ACADEMIC AND RESEARCH INSTITUTE IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 35 EUROPE CARDIAC SAFETY SERVICES MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 36 EUROPE CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 37 EUROPE IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 38 EUROPE HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 39 EUROPE COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 40 EUROPE CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)
TABLE 41 EUROPE CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 42 EUROPE CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 43 GERMANY CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 44 GERMANY IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 45 GERMANY HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 46 GERMANY COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 47 GERMANY CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)
TABLE 48 GERMANY CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 49 GERMANY CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 50 FRANCE CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 51 FRANCE IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 52 FRANCE HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 53 FRANCE COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 54 FRANCE CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)
TABLE 55 FRANCE CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 56 FRANCE CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 57 U.K. CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 58 U.K. IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 59 U.K. HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 60 U.K. COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 61 U.K. CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)
TABLE 62 U.K. CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 63 U.K. CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 64 ITALY CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 65 ITALY IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 66 ITALY HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 67 ITALY COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 68 ITALY CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)
TABLE 69 ITALY CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 70 ITALY CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 71 SPAIN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 72 SPAIN IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 73 SPAIN HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 74 SPAIN COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 75 SPAIN CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)
TABLE 76 SPAIN CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 77 SPAIN CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 78 TURKEY CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 79 TURKEY IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 80 TURKEY HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 81 TURKEY COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 82 TURKEY CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)
TABLE 83 TURKEY CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 84 TURKEY CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 85 RUSSIA CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 86 RUSSIA IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 87 RUSSIA HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 88 RUSSIA COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 89 RUSSIA CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)
TABLE 90 RUSSIA CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 91 RUSSIA CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 92 NETHERLANDS CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 93 NETHERLANDS IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 94 NETHERLANDS HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 95 NETHERLANDS COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 96 NETHERLANDS CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)
TABLE 97 NETHERLANDS CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 98 NETHERLANDS CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 99 SWITZERLAND CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 100 SWITZERLAND IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 101 SWITZERLAND HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 102 SWITZERLAND COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 103 SWITZERLAND CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)
TABLE 104 SWITZERLAND CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 105 SWITZERLAND CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 106 BELGIUM CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 107 BELGIUM IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 108 BELGIUM HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 109 BELGIUM COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 110 BELGIUM CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION)
TABLE 111 BELGIUM CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 112 BELGIUM CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 113 REST OF EUROPE CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
List of Figure
FIGURE 1 EUROPE CARDIAC SAFETY SERVICES MARKET: SEGMENTATION
FIGURE 2 EUROPE CARDIAC SAFETY SERVICES MARKET: DATA TRIANGULATION
FIGURE 3 EUROPE CARDIAC SAFETY SERVICES MARKET: DROC ANALYSIS
FIGURE 4 EUROPE CARDIAC SAFETY SERVICES MARKET: EUROPE VS COUNTRY MARKET ANALYSIS
FIGURE 5 EUROPE CARDIAC SAFETY SERVICES MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE CARDIAC SAFETY SERVICES MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 EUROPE CARDIAC SAFETY SERVICES MARKET: DBMR MARKET POSITION GRID
FIGURE 8 EUROPE CARDIAC SAFETY SERVICES MARKET: MARKET END USER GRID
FIGURE 9 EUROPE CARDIAC SAFETY SERVICES MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 EUROPE CARDIAC SAFETY SERVICES MARKET: SEGMENTATION
FIGURE 11 THE INCREASE IN DEMAND FOR CARDIAC SAFETY SERVICES ARE EXPECTED TO DRIVE THE EUROPE CARDIAC SAFETY SERVICES MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 12 ECG/HOLTER MEASUREMENTS SUBSTITUTE IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE CARDIAC SAFETY SERVICES MARKET IN 2022 & 2029
FIGURE 13 PATIENT FLOW DIAGRAM FOR ANY RANDOM DRUG
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE EUROPE CARDIAC SAFETY SERVICES MARKET
FIGURE 15 EUROPE CARDIAC SAFETY SERVICES MARKET: BY SERVICES, 2021
FIGURE 16 EUROPE CARDIAC SAFETY SERVICES MARKET: BY SERVICES, 2022-2029 (USD MILLION)
FIGURE 17 EUROPE CARDIAC SAFETY SERVICES MARKET: BY SERVICES, CAGR (2022-2029)
FIGURE 18 EUROPE CARDIAC SAFETY SERVICES MARKET: BY SERVICES, LIFELINE CURVE
FIGURE 19 EUROPE CARDIAC SAFETY SERVICES MARKET: BY PHASE, 2021
FIGURE 20 EUROPE CARDIAC SAFETY SERVICES MARKET: BY PHASE, 2022-2029 (USD MILLION)
FIGURE 21 EUROPE CARDIAC SAFETY SERVICES MARKET: BY PHASE, CAGR (2022-2029)
FIGURE 22 EUROPE CARDIAC SAFETY SERVICES MARKET: BY PHASE, LIFELINE CURVE
FIGURE 23 EUROPE CARDIAC SAFETY SERVICES MARKET: BY TYPE, 2021
FIGURE 24 EUROPE CARDIAC SAFETY SERVICES MARKET: BY TYPE, 2022-2029 (USD MILLION)
FIGURE 25 EUROPE CARDIAC SAFETY SERVICES MARKET: BY TYPE, CAGR (2022-2029)
FIGURE 26 EUROPE CARDIAC SAFETY SERVICES MARKET: BY TYPE, LIFELINE CURVE
FIGURE 27 EUROPE CARDIAC SAFETY SERVICES MARKET: BY END USER, 2021
FIGURE 28 EUROPE CARDIAC SAFETY SERVICES MARKET: BY END USER, 2022-2029 (USD MILLION)
FIGURE 29 EUROPE CARDIAC SAFETY SERVICES MARKET: BY END USER, CAGR (2022-2029)
FIGURE 30 EUROPE CARDIAC SAFETY SERVICES MARKET: BY END USER, LIFELINE CURVE
FIGURE 31 EUROPE CARDIAC SAFETY SERVICES MARKET: SNAPSHOT (2021)
FIGURE 32 EUROPE CARDIAC SAFETY SERVICES MARKET: BY COUNTRY (2021)
FIGURE 33 EUROPE CARDIAC SAFETY SERVICES MARKET: BY COUNTRY (2022 & 2029)
FIGURE 34 EUROPE CARDIAC SAFETY SERVICES MARKET: BY COUNTRY (2021 & 2029)
FIGURE 35 EUROPE CARDIAC SAFETY SERVICES MARKET: BY SERVICES (2022-2029)
FIGURE 36 EUROPE CARDIAC SAFETY SERVICES MARKET: COMPANY SHARE 2021 (%)
منهجية البحث
يتم جمع البيانات وتحليل سنة الأساس باستخدام وحدات جمع البيانات ذات أحجام العينات الكبيرة. تتضمن المرحلة الحصول على معلومات السوق أو البيانات ذات الصلة من خلال مصادر واستراتيجيات مختلفة. تتضمن فحص وتخطيط جميع البيانات المكتسبة من الماضي مسبقًا. كما تتضمن فحص التناقضات في المعلومات التي شوهدت عبر مصادر المعلومات المختلفة. يتم تحليل بيانات السوق وتقديرها باستخدام نماذج إحصائية ومتماسكة للسوق. كما أن تحليل حصة السوق وتحليل الاتجاهات الرئيسية هي عوامل النجاح الرئيسية في تقرير السوق. لمعرفة المزيد، يرجى طلب مكالمة محلل أو إرسال استفسارك.
منهجية البحث الرئيسية التي يستخدمها فريق بحث DBMR هي التثليث البيانات والتي تتضمن استخراج البيانات وتحليل تأثير متغيرات البيانات على السوق والتحقق الأولي (من قبل خبراء الصناعة). تتضمن نماذج البيانات شبكة تحديد موقف البائعين، وتحليل خط زمني للسوق، ونظرة عامة على السوق ودليل، وشبكة تحديد موقف الشركة، وتحليل براءات الاختراع، وتحليل التسعير، وتحليل حصة الشركة في السوق، ومعايير القياس، وتحليل حصة البائعين على المستوى العالمي مقابل الإقليمي. لمعرفة المزيد عن منهجية البحث، أرسل استفسارًا للتحدث إلى خبراء الصناعة لدينا.
التخصيص متاح
تعد Data Bridge Market Research رائدة في مجال البحوث التكوينية المتقدمة. ونحن نفخر بخدمة عملائنا الحاليين والجدد بالبيانات والتحليلات التي تتطابق مع هدفهم. ويمكن تخصيص التقرير ليشمل تحليل اتجاه الأسعار للعلامات التجارية المستهدفة وفهم السوق في بلدان إضافية (اطلب قائمة البلدان)، وبيانات نتائج التجارب السريرية، ومراجعة الأدبيات، وتحليل السوق المجدد وقاعدة المنتج. ويمكن تحليل تحليل السوق للمنافسين المستهدفين من التحليل القائم على التكنولوجيا إلى استراتيجيات محفظة السوق. ويمكننا إضافة عدد كبير من المنافسين الذين تحتاج إلى بيانات عنهم بالتنسيق وأسلوب البيانات الذي تبحث عنه. ويمكن لفريق المحللين لدينا أيضًا تزويدك بالبيانات في ملفات Excel الخام أو جداول البيانات المحورية (كتاب الحقائق) أو مساعدتك في إنشاء عروض تقديمية من مجموعات البيانات المتوفرة في التقرير.
